Organovo says it has run out of money to advance its efforts to develop 3-D “patches” of living human liver tissue to tide over people waiting for an organ transplant.
The San Diego-based biotech has been working since 2007 to use a method known as bio-printing to come up with such a product, which Organovo (NASDAQ: ONVO) was developing for patients with end-stage liver disease and a group of rare diseases that also necessitate organ transplantation. In the meantime, the company built a business as a contract research organization around its 3-D human tissue cultures, which pharma companies have used… Read more »
UNDERWRITERS AND PARTNERS
